U.S. Markets closed

F-star Therapeutics, Inc. (FSTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.20-0.03 (-0.48%)
At close: 4:00PM EDT

F-star Therapeutics, Inc.

Eddeva B920
Babraham Research Campus
Cambridge CB22 3AT
United Kingdom
44 1223 497 400

Full Time Employees75

Key Executives

NameTitlePayExercisedYear Born
Dr. Eliot Richard Forster M.B.A., Ph.D.Pres, CEO & Director1.05MN/A1966
Ms. Darlene M. Deptula-HicksCFO & Treasurer672.38kN/A1957
Dr. Neil BrewisChief Scientific Officer594.4kN/AN/A
Dr. Louis KayitalireChief Medical Officer716.89kN/AN/A
Lindsey TrickettVP of Investor Relations & CommunicationsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.

Corporate Governance

F-star Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.